Retatrutide: Triple Receptor Agonism & 24% Weight Reduction at 48 Weeks
A Phase 2 randomized, double-blind trial published in Nature Medicine demonstrated retatrutide 8–12mg produced mean body weight reductions of 22.8–24.2% over 48 weeks, alongside up to 82% liver fat reduction in MASLD patients.
Nature Medicine, Sanyal et al. 2024 · DOI: 10.1038/s41591-024-03018-2
View on PubMed